Roche have, today, announced plans to enter a merger agreement to acquire Spark Therapeutics.
Spark Therapeutics are a leader in discovering, developing and delivering gene therapies – they are the only biotech company that has successfully commercialised a gene therapy for a genetic disease in the US.
Though this is not directly linked to treatment advancements for people with type 1 diabetes, this move could one day benefit people like my son who have type 1.
For more detailed information on the merger agreement please see the below link:
Roche merger agreement to acquire Spark Therapeutics